A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

• Principais autores: Spagnuolo V (Autor), Galli L (Autor), Poli A (Autor), Bigoloni A (Autor), Fumagalli L (Autor), Gianotti N (Autor), Nozza S (Autor), Ferrari D (Autor), Locatelli M (Autor), Lazzarin A (Autor), Castagna A (Autor)
• Formato: Livro
• Publicado em: Dove Medical Press, 2019-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Vincenzo Spagnuolo,1,2 Laura Galli,2 Andrea Poli,2 Alba Bigoloni,2 Luca Fumagalli,2 Nicola Gianotti,2 Silvia Nozza,2 Davide Ferrari,3 Massimo Locatelli,3 Adriano Lazzarin,2 Antonella Castagna1,2 1Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy; 2Clinic of Infectiou...